Therapeutical strategies for treatment resistant depression;Therapieresistente depression

Wiener Medizinische Wochenschrift

Volumn 149, Issue 18, 1999, Pages 511-514

  Hatzinger, M ^a   Holsboer Trachsler, Edith ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b NONE

Author keywords

Antidepressants; Depression; Lithium; Thyroid hormone; Treatment resistance

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; IMIPRAMINE; LIOTHYRONINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PINDOLOL; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VENLAFAXINE;

DEPRESSION; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HUMAN; PRACTICE GUIDELINE; REVIEW; SLEEP DEPRIVATION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM CARBONATE; TREATMENT FAILURE; TRIIODOTHYRONINE;

EID: 0032786107     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Derivan A, Entsuah AR, Kikta D: Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol Bull 1995;31:439-447.
2. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR: CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991;11:127-132.
3. Goetze U, Tölle R: Antidepressive Wirkung des partiellen Schlafentzugs während der I. Hälfte der Nacht. Psychiatr Clin 1981;14:129-149.
4. Holsboer-Trachsler E: Neurobiologische und psychopathologische Verlaufsmessungen bei Depressionstherapie, Trimipramin, Schlafentzug und Licht. Bibliotheca Psychiatrica No. 166. Saletu B (Hrsg.), Karger, Basel, 1994.
5. Holsboer-Trachsler E, Ernst K: Sustained antidepressive effect of repeated partial sleep deprivation. Psychopathology 1986;19:172-176.
6. Howland RH, Thase ME: Switching strategies for the treatment of unipolar major depression. In: Rush AJ (Hrsg) Mood Disorders - Systematic medication management. Karger, Basel/London/New York, 1997.
7. Janicak PG, Davis JM, Gibbons RD, Ericksen S, Chang S, Gallagher P: Efficacy of ECT: a meta-analysis. Am J Psychiatry 1985;142:297-302.
8. Joffe RT, Singer W: A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990;32:241-251.
9. Joffe RT, Singer W, Levitt AJ, MacDonald C: A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-393.
10. Kasper S: Therapeutischer Schlafentzug und antidepressive Medikation. In: Kasper S, Möller HJ (Hrsg): Therapeutischer Schlafentzug, Springer, Wien/New York, 1996, pp 55-67.
11. Kasper S, Voll G, Vieira A, Kick H: Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression - Results of a double-blind study. Pharmacopsychiatry 1990;23:135-142.
12. Kielholz P, Terzani S, Gasipar M: Behandlung der therapieresistenten Depressionen. Dt Med Wochenschr 1978;103:241-243.
13. Kragh-Sorensen P, Hansen CE, Baastrup PC, Hvidberg EF: Self-inhibiting action of nortriptylin's antidepressive effect at high plasma levels; a randomized double-blind study controlled by plasma concentrations in patients with endogenous depression. Psychopharmacologia 1976;45:305-312.
14. Nelson JC: Augmentation strategies for treatment of unipolar depression. In: Rush A J (ed): Mood Disorders. Systematic Medication Management. Karger, Basel (1997) pp 34-55.
15. Nelson JC, Mazure CM, Bowers MB, Jatlow PI: A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307.
16. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J: Venlafaxine for treatment-resistent unipolar depression. J Clin Psychopharmacol 1994;14:419-423.
17. Oppenheim G, Zohar J, Shapiro B, Belmaker RH: The role of estrogen in treating resistant depression. In: Zohar J, Belmaker (Hrsg) Treating resistant depression. PMA Publishing, New York pp (1987) 357-366.
18. Prange AJ, Wilson JC, Rabon AM: Enhancement of imipramine anti-depressant activity by thyroid hormone. Am J Psychiatry 1969; 126:457-469.
19. Satel SL, Nelson JC: Stimulants in the treatment of depression: A critical overview. J Clin Psychiatry 1989;50:241-249.
20. Schilgen B, Tölle R: Partial sleep deprivation as therapy for depression. Arch Gen Psychiatry 1980;37:267-271.
21. Spiker DG, Weiss JC, Delay RS, Griffin SJ: The pharmacological treatment of delusional depression. Am J Psychiatry 1985;142:430-436.
22. Thase ME, Rush AJ, Kasper S, Nemeroff CB: Tricyclics and newer antidepressant medications: Treatment options for treatment-resistant depressions. Depression 1995;2:152-168.
23. van den Hoofdakker RH, Gordijin MCM, Kasper S: Sleep deprivation in refractory depression. In: Nolen WA, Zohar J, Roose SP; Amsterdam JD (Hrsg) Refractory depression: current strategies and furture directions. John Wiley, (1994) pp 129-142.
24. Wellgesundheitsorganisation, WHO: Internationale Klassifikation psychischer Störungen. In: Dilling H, Mombour W, Schmidt MH (eds): ICD-10 Hans Huber, Bern/Göttingen/Toronto, 1991.
25. World Psychiatric Association: Symposium of therapy resistant depression. Pharmacopsychiatry 1974;7:69-224.
26. Wu JC, Bunney WE: The biological basis of antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 1990;147:14-21.